×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
BPMC – blueprint medicines corporation (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
BPMC
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
1/2
08:16 am
bpmc
Blueprint Medicines Co. (NASDAQ: BPMC) had its "overweight" rating re-affirmed by analysts at Stephens. They now have a $140.00 price target on the stock.
Low
Report
Blueprint Medicines Co. (NASDAQ: BPMC) had its "overweight" rating re-affirmed by analysts at Stephens. They now have a $140.00 price target on the stock.
12/18
08:14 am
bpmc
Blueprint Medicines to Present at the 43rd Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Medium
Report
Blueprint Medicines to Present at the 43rd Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
12/18
08:00 am
bpmc
Blueprint Medicines to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Medium
Report
Blueprint Medicines to Present at the 43rd Annual J.P. Morgan Healthcare Conference
12/11
12:30 pm
bpmc
Blueprint Medicines Co. (NASDAQ: BPMC) had its "buy" rating re-affirmed by analysts at Guggenheim.
Low
Report
Blueprint Medicines Co. (NASDAQ: BPMC) had its "buy" rating re-affirmed by analysts at Guggenheim.
12/9
11:17 am
bpmc
Blueprint Medicines Co. (NASDAQ: BPMC) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $125.00 price target on the stock.
Low
Report
Blueprint Medicines Co. (NASDAQ: BPMC) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $125.00 price target on the stock.
12/7
12:35 pm
bpmc
Blueprint Medicines' Continued Leadership in Redefining the Standard of Care in Systemic Mastocytosis Highlighted at 2024 ASH Annual Meeting [Yahoo! Finance]
Low
Report
Blueprint Medicines' Continued Leadership in Redefining the Standard of Care in Systemic Mastocytosis Highlighted at 2024 ASH Annual Meeting [Yahoo! Finance]
12/7
12:30 pm
bpmc
Blueprint Medicines' Continued Leadership in Redefining the Standard of Care in Systemic Mastocytosis Highlighted at 2024 ASH Annual Meeting
Low
Report
Blueprint Medicines' Continued Leadership in Redefining the Standard of Care in Systemic Mastocytosis Highlighted at 2024 ASH Annual Meeting
12/3
06:03 am
bpmc
30 Under 30 Healthcare 2025: Advancing AI, Delivering Care And Creating New Therapies [Forbes]
Low
Report
30 Under 30 Healthcare 2025: Advancing AI, Delivering Care And Creating New Therapies [Forbes]
Date
Time
Symbol
Company Name
Action
%Chg
10/30/2024
07:00 am
bpmc
blueprint medicines corporation
BEAT
Report
5.5%
blueprint medicines corporation
8/1/2024
07:00 am
bpmc
blueprint medicines corporation
BEAT
Report
-7.4%
blueprint medicines corporation
5/2/2024
07:00 am
bpmc
blueprint medicines corporation
BEAT
Report
7.0%
blueprint medicines corporation
2/15/2024
07:00 am
bpmc
blueprint medicines corporation
BEAT
Report
14.0%
blueprint medicines corporation
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/20
04:15 pm
bpmc
Form 4 Blueprint Medicines Corp For: Dec 18 Filed by: Rossi Christina
Low
Report
Form 4 Blueprint Medicines Corp For: Dec 18 Filed by: Rossi Christina
12/20
04:15 pm
bpmc
Form 4 Blueprint Medicines Corp For: Dec 19 Filed by: Albers Jeffrey W.
Low
Report
Form 4 Blueprint Medicines Corp For: Dec 19 Filed by: Albers Jeffrey W.
12/19
05:18 pm
bpmc
Form 144 Blueprint Medicines Corp Filed by: Albers Jeffrey W.
Low
Report
Form 144 Blueprint Medicines Corp Filed by: Albers Jeffrey W.
12/18
04:32 pm
bpmc
Form 8-K Blueprint Medicines Corp For: Dec 13
Low
Report
Form 8-K Blueprint Medicines Corp For: Dec 13
12/16
07:52 pm
bpmc
Form 4 Blueprint Medicines Corp For: Dec 12 Filed by: Hurley Ariel
Low
Report
Form 4 Blueprint Medicines Corp For: Dec 12 Filed by: Hurley Ariel
12/12
04:52 pm
bpmc
Form 144 Blueprint Medicines Corp Filed by: Hurley Ariel
Low
Report
Form 144 Blueprint Medicines Corp Filed by: Hurley Ariel
12/3
05:34 pm
bpmc
Form 4 Blueprint Medicines Corp For: Nov 29 Filed by: Haviland Kate
Low
Report
Form 4 Blueprint Medicines Corp For: Nov 29 Filed by: Haviland Kate
12/2
06:53 pm
bpmc
Form 4 Blueprint Medicines Corp For: Nov 27 Filed by: Rossi Christina
Low
Report
Form 4 Blueprint Medicines Corp For: Nov 27 Filed by: Rossi Christina
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/16
Blueprint Medicines Corp (NASDAQ: BPMC) was upgraded by analysts at Deutsche Bank AG from a "hold" rating to a "buy" rating.
22.1%
3/24 Blueprint Medicines Corp (NASDAQ: BPMC) had its "outperform" rating re-affirmed by analysts at Wedbush. 11.5%
3/19 Blueprint Medicines Corp (NASDAQ: BPMC) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 8.1%
5/9 Q1/2019 3/31/2019 EPS -1.980 ZacksConsensus -1.830 ActVsEst (0.150) - Miss 7.2%
6/4 Form 8-K Blueprint Medicines Corp For: Jun 03 6.8%
2/14 Blueprint Medicines (BPMC) Q4 2019 Earnings Call Transcript [The Motley Fool] 6.3%
3/25 Form 4 Blueprint Medicines Corp For: Mar 23 Filed by: Albers Jeffrey W. 6.2%
6/5 Blueprint Medicines Corp (NASDAQ: BPMC) was upgraded by analysts at ValuEngine from a "buy" rating to a "strong-buy" rating. 5.7%
3/3 Form 4 Blueprint Medicines Corp For: Mar 01 Filed by: Dorsch Marion 5.2%
11/5 Form 4 Blueprint Medicines Corp For: Nov 01 Filed by: Rossi Christina 5.1%
3/24 Blueprint Medicines Corp (NASDAQ: BPMC) had its "outperform" rating re-affirmed by analysts at Wedbush. 11.5%
3/19 Blueprint Medicines Corp (NASDAQ: BPMC) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 8.1%
5/9 Q1/2019 3/31/2019 EPS -1.980 ZacksConsensus -1.830 ActVsEst (0.150) - Miss 7.2%
6/4 Form 8-K Blueprint Medicines Corp For: Jun 03 6.8%
2/14 Blueprint Medicines (BPMC) Q4 2019 Earnings Call Transcript [The Motley Fool] 6.3%
3/25 Form 4 Blueprint Medicines Corp For: Mar 23 Filed by: Albers Jeffrey W. 6.2%
6/5 Blueprint Medicines Corp (NASDAQ: BPMC) was upgraded by analysts at ValuEngine from a "buy" rating to a "strong-buy" rating. 5.7%
3/3 Form 4 Blueprint Medicines Corp For: Mar 01 Filed by: Dorsch Marion 5.2%
11/5 Form 4 Blueprint Medicines Corp For: Nov 01 Filed by: Rossi Christina 5.1%
TOP News Decliners
4/28
Blueprint Medicines Announces Top-line Results from Phase 3 VOYAGER Trial of Avapritinib versus Regorafenib in Patients with Advanced Gastrointestinal Stromal Tumor
-17.3%
3/16 Form CT ORDER Blueprint Medicines Corp -13.7%
10/28 Form 8-K Blueprint Medicines Corp For: Oct 25 -13.7%
1/21 Form 424B5 Blueprint Medicines Corp -12.4%
12/6 Form 4 Blueprint Medicines Corp For: Dec 04 Filed by: Hurley Ariel -10.9%
1/13 Form 8-K Blueprint Medicines Corp For: Jan 13 -10.6%
3/11 Form 4 Blueprint Medicines Corp For: Mar 09 Filed by: Rossi Christina -7.2%
3/17 Form SEC STAFF LETTER Blueprint Medicines Corp -6.5%
8/1 Form 8-K Blueprint Medicines Corp For: Aug 01 -6.3%
9/9 Lilly's targeted RET drug shrinks tumors in lung cancer trial [Reuters] -6.1%
3/16 Form CT ORDER Blueprint Medicines Corp -13.7%
10/28 Form 8-K Blueprint Medicines Corp For: Oct 25 -13.7%
1/21 Form 424B5 Blueprint Medicines Corp -12.4%
12/6 Form 4 Blueprint Medicines Corp For: Dec 04 Filed by: Hurley Ariel -10.9%
1/13 Form 8-K Blueprint Medicines Corp For: Jan 13 -10.6%
3/11 Form 4 Blueprint Medicines Corp For: Mar 09 Filed by: Rossi Christina -7.2%
3/17 Form SEC STAFF LETTER Blueprint Medicines Corp -6.5%
8/1 Form 8-K Blueprint Medicines Corp For: Aug 01 -6.3%
9/9 Lilly's targeted RET drug shrinks tumors in lung cancer trial [Reuters] -6.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: